Stock Track | Akeso Soars on Promising Late-Stage Cancer Drug Trial Results

Stock Track09-10

Shares of Hong Kong-based biotech company Akeso Inc. (HKG:9926) skyrocketed over 16% in intraday trading on Monday, fueled by investor enthusiasm over positive Phase III trial results for the company's new cancer drug IVONESCIMAB.

Akeso presented the late-stage trial data at the IASLC 2024 World Conference on Lung Cancer, showing that IVONESCIMAB demonstrated statistically significant improvement and clinically meaningful benefit in treating EGFR mutated locally advanced or metastatic non-squamous non-small cell lung cancer patients, as compared to existing therapies.

The promising Phase III results represent a major milestone for Akeso's IVONESCIMAB program and pave the way for the biotech firm to seek regulatory approvals to bring the innovative lung cancer treatment to market. Lung cancer remains one of the most difficult cancers to treat, so a new effective therapy could significantly improve patient outcomes and create a lucrative commercial opportunity for Akeso if approved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136450656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136450656","market":"hk","top_or_hot":-1,"title":"Stock Track | Akeso Soars on Promising Late-Stage Cancer Drug Trial Results","media":"Stock Track","content":"<p>Shares of Hong Kong-based biotech company Akeso Inc. (HKG:9926) skyrocketed over 16% in intraday trading on Monday, fueled by investor enthusiasm over positive Phase III trial results for the company's new cancer drug IVONESCIMAB.</p>\n\n<p>Akeso presented the late-stage trial data at the IASLC 2024 World Conference on Lung Cancer, showing that IVONESCIMAB demonstrated statistically significant improvement and clinically meaningful benefit in treating EGFR mutated locally advanced or metastatic non-squamous non-small cell lung cancer patients, as compared to existing therapies.</p>\n\n<p>The promising Phase III results represent a major milestone for Akeso's IVONESCIMAB program and pave the way for the biotech firm to seek regulatory approvals to bring the innovative lung cancer treatment to market. Lung cancer remains one of the most difficult cancers to treat, so a new effective therapy could significantly improve patient outcomes and create a lucrative commercial opportunity for Akeso if approved.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Akeso Soars on Promising Late-Stage Cancer Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Akeso Soars on Promising Late-Stage Cancer Drug Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-10 09:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Hong Kong-based biotech company Akeso Inc. (HKG:9926) skyrocketed over 16% in intraday trading on Monday, fueled by investor enthusiasm over positive Phase III trial results for the company'...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1136450656","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136450656","pubTimestamp":1725931967,"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hong Kong-based biotech company Akeso Inc.  skyrocketed over 16% in intraday trading on Monday, fueled by investor enthusiasm over positive Phase III trial results for the company's new cancer drug IVONESCIMAB.Akeso presented the late-stage trial data at the IASLC 2024 World Conference on Lung Cancer, showing that IVONESCIMAB demonstrated statistically significant improvement and clinically meaningful benefit in treating EGFR mutated locally advanced or metastatic non-squamous non-smal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"康方生物股票因晚期癌症药物试验结果有希望而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"Shares of Hong Kong-based biotech company Akeso Inc. (HKG:9926) skyrocketed over 16% in intraday trading on Monday, fueled by investor enthusiasm over positive Phase III trial results for the company's new cancer drug IVONESCIMAB.\nAkeso presented the late-stage trial data at the IASLC 2024 World Conference on Lung Cancer, showing that IVONESCIMAB demonstrated statistically significant improvement and clinically meaningful benefit in treating EGFR mutated locally advanced or metastatic non-squamous non-small cell lung cancer patients, as compared to existing therapies.\nThe promising Phase III results represent a major milestone for Akeso's IVONESCIMAB program and pave the way for the biotech firm to seek regulatory approvals to bring the innovative lung cancer treatment to market. Lung cancer remains one of the most difficult cancers to treat, so a new effective therapy could significantly improve patient outcomes and create a lucrative commercial opportunity for Akeso if approved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136450656"}